Pharmacies are struggling to keep up with the demand for drugs as a result of a surge in infections in Europe.
The new version of ibuprofen, the most widely used painkiller in the United Kingdom, was first approved for sale in Britain in 2016 and now comes in a range of colours, including blue, green and pink.
The brand has also been rebranded as GlucoQuad and is being sold under the brand name Quad.
In the US, the drug is sold under a different brand name, Otsuka.
A spokesman for the British Pharmacopoeia said the new version would be available in pharmacies starting on March 5.
“This is a brand-new version of the brand, and the changes in colour will not be visible to the consumer,” he said.
“The drug is being available in pharmacy stores at this time.”
Glucoquad is available as a generic medicine and can be purchased in pharmacies for $8.80 to $10.20 a pill, or $14.40 to $17.20 for a 12-pack.”
In the UK, the new ibuprophen is the brand-name version and the new generic versions are being distributed as generic medicines.”
Glucoquad is available as a generic medicine and can be purchased in pharmacies for $8.80 to $10.20 a pill, or $14.40 to $17.20 for a 12-pack.
Otsuka is available under a brand name of Gluconium.
Otsukas is also available as generic medicine, and can cost $15 to $20 a tablet.
In Europe, a brand named GluCOVID-19 has been developed by a pharmaceutical company, Pfizer.
GluCOVI-19, also known as coronavirus, is a strain of coronaviruses that is the most deadly and deadliest to humans.
In Britain, more than 10,000 coronaviral infections were recorded in the first half of 2018, the highest figure in Europe, according to the National Health Service.
The UK is not the only country to have seen a rise in infections linked to the coronavirence.
The US saw an 8 per cent increase in cases in June.
In a statement, the National Institute of Allergy and Infectious Diseases said the US figure was “a direct result of the recent resurgence in coronavids, which is in turn a direct result in the continued rapid spread of the novel coronavviruses.”
It is important to note that the coronavecovirus pandemic is still in its infancy and is still largely driven by the pandemic itself, and that it is important for patients to take the appropriate measures to protect themselves and their loved ones.””
The global response to this pandemic has been exceptional and the number of infections continues to decline year-on-year,” the institute said.”
There is a clear need to focus on the prevention and control of new coronavides as a means of controlling coronavioliosis.”
British pharmacy keeper Ian Smith, who is based in London, said he was happy with the news.”
I was just delighted to be told that Gluquad will be available to buy in pharmacy shops across the UK at this early stage.
“The whole brand has been in the pipeline for some time, and I think it’s good that it has finally been launched in the marketplace, which has been a long time coming.”
“I’m looking forward to the day I can get a refill.”
In an interview with the BBC, Mr Smith said the decision was a positive one.
“We are doing what is best for the people of Britain and I feel like we have a responsibility to the NHS,” he added.
“If we don’t do what is right, then we are not going to be able to save the NHS.”
The UK has one of the highest rates of coronavecanine infections in the world, with the number exceeding 200,000.
The pandemic began in late February, with more than 1,300 cases reported in the US.
More than 60,000 people have died.